{"filing":{"accession_number":"0001140361-26-035055","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"ef20081330_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/ef20081330_8k.htm"},"events":[{"id":30580,"run_id":28029,"accession_number":"0001140361-26-035055","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine (Attruby) and lower drug costs, with the company expecting to avoid future pricing mandates. This is a material strategic and regulatory agreement affecting the company's commercial operations and pricing framework, but it does not fit neatly into the specific event categories (not M\u0026A, not a restatement, not a covenant breach, not litigation). The agreement is operational and regulatory in nature, affecting market access and pricing policy going forward.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33212,"accession_number":"0001140361-26-035055","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine (Attruby) and lower drug costs, with the company expecting to avoid future pricing mandates. This is a material strategic and regulatory agreement affecting the company's commercial operations and pricing framework, but it does not fit neatly into the specific event categories (not M\u0026A, not a restatement, not a covenant breach, not litigation). The agreement is operational and regulatory in nature, affecting market access and pricing policy going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T19:55:40.636595+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33212,"accession_number":"0001140361-26-035055","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine (Attruby) and lower drug costs, with the company expecting to avoid future pricing mandates. This is a material strategic and regulatory agreement affecting the company's commercial operations and pricing framework, but it does not fit neatly into the specific event categories (not M\u0026A, not a restatement, not a covenant breach, not litigation). The agreement is operational and regulatory in nature, affecting market access and pricing policy going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T19:55:40.636595+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-31"}]}